Endothelial Adenosine Monophosphate-Activated Protein Kinase-Alpha1 Deficiency Potentiates Hyperoxia-Induced

Ahmed Elsaie1,2, Renuka T Menon1, Amrit K Shrestha1

  • 1Department of Pediatrics, Neonatology Section, Baylor College of Medicine (BCM), Houston, TX 77030, USA.

Insights

Adenosine monophosphate-activated protein kinase alpha1 (AMPKα1) protects neonatal mice against bronchopulmonary dysplasia and pulmonary hypertension. AMPKα1 is essential for preventing lung injury and promoting angiogenesis in premature infants.

Area of Science:

  • Biomedical research
  • Pulmonary medicine
  • Neonatology

Background:

  • Bronchopulmonary dysplasia and pulmonary hypertension (BPD-PH) are chronic lung disorders in premature infants.
  • Hyperoxia is a known cause of BPD-PH, and its effect on adenosine monophosphate-activated protein kinase alpha1 (AMPKα1) in neonatal lungs is not fully understood.

Purpose of the Study:

  • To investigate the role of endothelial AMPKα1 in protecting neonatal mice against hyperoxia-induced BPD-PH.
  • To determine if AMPKα1 knockdown affects angiogenesis in human pulmonary microvascular endothelial cells (HPMECs) exposed to hyperoxia.

Main Methods:

  • Lung morphometric and echocardiographic studies were performed on endothelial AMPKα1-sufficient and -deficient mice exposed to normoxia or hyperoxia.
  • Tubule formation assays and proliferating cell nuclear antigen expression analysis were conducted on HPMECs with or without AMPKα1 knockdown under normoxic or hyperoxic conditions.

Main Results:

  • Endothelial AMPKα1 deficiency exacerbated hyperoxia-induced lung simplification, vascular remodeling, and pulmonary hypertension in neonatal mice.
  • AMPKα1 knockdown reduced tubule formation and proliferating cell nuclear antigen expression in HPMECs, indicating impaired angiogenesis.

Conclusions:

  • Endothelial AMPKα1 is crucial for mitigating hyperoxia-induced BPD-PH in neonatal mice.
  • AMPKα1 promotes angiogenesis in pulmonary microvascular endothelial cells, offering a protective mechanism against hyperoxia-induced lung injury.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
238
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
317
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.3K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
422
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
2.6K